Company intelligence / Profile preview
BEAT BioTherapeutics
Seattle, Washington, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
BEAT BioTherapeutics has demonstrated in small and large animal models of heart failure that a single dose of gene therapy targeting ribonucleotide reductase led to sustained inotropic effects with no toxicity or safety concerns identified to date, with the goal of testing this agent in patients with heart failure
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Gene therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on BEAT BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BEAT BioTherapeutics.